1037 related articles for article (PubMed ID: 35007724)
21. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
22. Targeting EGFR tyrosine kinase: Synthesis, in vitro antitumor evaluation, and molecular modeling studies of benzothiazole-based derivatives.
Mokhtar AM; El-Messery SM; Ghaly MA; Hassan GS
Bioorg Chem; 2020 Nov; 104():104259. PubMed ID: 32919134
[TBL] [Abstract][Full Text] [Related]
23. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
24. Exploration of N-alkyl-2-[(4-oxo-3-(4-sulfamoylphenyl)-3,4-dihydroquinazolin-2-yl)thio]acetamide derivatives as anticancer and radiosensitizing agents.
Soliman AM; Ghorab MM
Bioorg Chem; 2019 Jul; 88():102956. PubMed ID: 31054432
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
26. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
28. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel ureido benzothiophenes as dual VEGFR-2/EGFR anticancer agents.
Eldehna WM; Al-Ansary GH; Al-Warhi T; Jaballah MY; Elaasser M; Rashed M
Bioorg Chem; 2024 Feb; 143():107037. PubMed ID: 38134521
[TBL] [Abstract][Full Text] [Related]
30. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
[TBL] [Abstract][Full Text] [Related]
32. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
35. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
Molecules; 2021 May; 26(10):. PubMed ID: 34069962
[TBL] [Abstract][Full Text] [Related]
37. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]